title: The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
abstract: Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD.
authors.affiliation: Servicio de Nefrología e Hipertensión, Fundación Jiménez Díaz, Universidad Autonoma, Madrid, CIBERDEM, FRIAT, España. Electronic address: JEgido@fjd.es.
authors.forename: Jesús
authors.initials: J
authors.lastname: Egido
authors.affiliation: Servicio de Nefrología, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Alberto
authors.initials: A
authors.lastname: Martínez-Castelao
authors.affiliation: Servicio de Nefrología, Fundación Puigvert, Barcelona, España.
authors.forename: Jordi
authors.initials: J
authors.lastname: Bover
authors.affiliation: Servicio de Nefrología, Hospital 12 de Octubre, Madrid, España.
authors.forename: Manuel
authors.initials: M
authors.lastname: Praga
authors.affiliation: Servicio de Nefrología, Hospital Clínic, Barcelona, España.
authors.forename: José Vicente
authors.initials: JV
authors.lastname: Torregrosa
authors.affiliation: Servicio de Nefrología, Hospital Universitario Arnau de Vilanova, Lleida, España.
authors.forename: Elvira
authors.initials: E
authors.lastname: Fernández-Giráldez
authors.affiliation: Servicio de Nefrología, Hospital Virgen del Camino, Pamplona, Navarra, España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Solozábal
mesh_terms: D004872:Ergocalciferols / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D008903:Minerals; D010281:Parathyroid Hormone; D010758:Phosphorus; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: D004872:Ergocalciferols; D008903:Minerals; D010281:Parathyroid Hormone; D010758:Phosphorus; C084656:paricalcitol
keywords: Aterosclerosis; Atherosclerosis; Calcificación vascular; Dialysis; Diálisis; Hiperparatiroidismo secundario; Hormona paratiroidea; Parathyroid hormone; Proteinuria; Secondary hyperparathyroidism; Transplant; Trasplante; Vascular calcification; Vitamin D; Vitamina D